- Home
- BBIO
as 03-28-2025 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | 730 | City: | PALO ALTO |
| Market Cap: | 6.7B | IPO Year: | 2019 |
| Target Price: | $52.90 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $39.47 | Next Earning Date: | 05-01-2025 |
| Revenue: | $221,902,000 | Revenue Growth: | 2285.27% |
| Revenue Growth (this year): | 6.31% | Revenue Growth (next year): | 131.17% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Mar 25 '25 | Sell | $36.87 | 75,000 | $2,764,942.50 | 4,948,447 | |
| Valantine Hannah | BBIO | Director | Mar 6 '25 | Sell | $32.58 | 12,875 | $419,499.69 | 1,764 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | Mar 5 '25 | Sell | $32.96 | 6,000,000 | $197,760,000.00 | 19,260,971 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 25 '25 | Sell | $33.58 | 75,000 | $2,517,971.14 | 4,948,447 | |
| STEPHENSON BRIAN C | BBIO | CFO and Treasurer | Feb 25 '25 | Sell | $33.68 | 8,500 | $282,114.88 | 102,464 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 16 '25 | Sell | $36.35 | 31,543 | $1,140,024.26 | 4,948,447 | |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Feb 16 '25 | Sell | $36.16 | 4,148 | $149,973.43 | 102,464 | |
| VIKING GLOBAL INVESTORS LP | BBIO | 10% Owner | Jan 31 '25 | Sell | $34.90 | 3,065,616 | $106,989,998.40 | 22,055,375 | |
| Kumar Neil | BBIO | Chief Executive Officer | Jan 28 '25 | Sell | $36.48 | 600,000 | $21,788,650.42 | 4,948,447 | |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Jan 28 '25 | Sell | $36.29 | 68,000 | $2,467,760.80 | 102,464 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition
GlobeNewswire
2 days ago
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewswire
5 days ago
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
Investor's Business Daily
8 days ago
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
GlobeNewswire
8 days ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Pharmaceutical Technology
8 days ago
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
The Wall Street Journal
8 days ago
Alnylam Stock Jumps After the FDA Approves Its Heart Drug
Bloomberg
8 days ago
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.